PubRank

J Bennouna

Author PubWeight™ 21.49‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer. J Med Econ 2013 1.92
2 Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1. Ann Oncol 2001 1.28
3 Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Ann Oncol 2013 1.06
4 Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer. Br J Cancer 2009 0.94
5 Negative influence of delayed surgery on survival after preoperative radiotherapy in rectal cancer. Colorectal Dis 2006 0.92
6 Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. Br J Cancer 2011 0.91
7 Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6. Oncology 2011 0.89
8 Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study. Br J Cancer 2001 0.87
9 Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. Ann Oncol 2002 0.87
10 Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer. Br J Cancer 2007 0.86
11 Patient preference for either the EORTC QLQ-C30 or the FACIT Quality Of Life (QOL) measures: a study performed in patients suffering from carcinoma of an unknown primary site (CUP). Eur J Cancer 2004 0.86
12 Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial. Br J Cancer 2011 0.85
13 Protective role of Bcl2 in metabolic oxidative stress-induced cell death. J Cell Sci 2001 0.84
14 Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer. Ann Oncol 2013 0.84
15 Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients. Ann Oncol 2002 0.83
16 Adjuvant chemotherapy for colon cancer: a confusing area! Ann Oncol 2005 0.79
17 Phase I trial of interleukin-2 and high-dose arginine butyrate in metastatic colorectal cancer. Cancer Immunol Immunother 2000 0.79
18 Non-small-cell lung cancer: should histology guide chemotherapy treatment? Ann Oncol 2009 0.79
19 Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors. Cancer Chemother Pharmacol 2012 0.77
20 [Molecular biology of lung cancer series]. Rev Mal Respir 2010 0.77
21 Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. Chemotherapy 2012 0.76
22 Resection of hepatic and pulmonary metastases in patients with colorectal cancer. Am J Clin Oncol 2001 0.76
23 Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer. Cancer Chemother Pharmacol 2013 0.75
24 A phase II trial of raltitrexed (Tomudex) in advanced pancreatic and biliary carcinoma. Oncology 2005 0.75
25 Thyroglobulin monitoring after treatment of well-differentiated thyroid cancer. Eur J Surg Oncol 2004 0.75
26 [Towards a histologically guided management for NSCLC]. Rev Mal Respir 2009 0.75
27 [Bevacizumab and arterial hypertension or proteinuria: management]. Rev Mal Respir 2008 0.75
28 Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction. Invest New Drugs 2012 0.75
29 [Thrombo-embolic risks and bevacizumab: data from the literature and recommendations for the use of anticoagulants and antiaggregants]. Rev Mal Respir 2008 0.75